The Oncology Market and ESMO 2023 Highlights & Implications
Duration: 60 minutes The 2023 European Society for Medical Oncology (ESMO) annual meeting will feature important clinical updates on a number of checkpoint inhibitor, cell therapy and targeted programs. Join Bloomberg Intelligence analysts John Murphy and Max Nisen, and NYU Langone's Vamsidhar Velcheti, MD as they discuss the highlights, which will likely include full Tropion-Lung01 details from AstraZeneca's datopotamab deruxtecan, updated Destiny-Breast04 survival data from AstraZeneca/Daiichi Sankyo's Enhertu and initial prostate cancer results from Amgen's Steap1 x CD3 bispecific.
Speakers
John Murphy
Senior Research Analyst
Bloomberg Intelligence
John Murphy is a senior equity analyst at Bloomberg Intelligence focused on large-cap Pharma. Prior to joining Bloomberg in 2021 John was a partner at Arkle Associates, an independent healthcare advisory company, and before that spent the majority of his career in healthcare equity research at Goldman Sachs. Additional experience includes working in drug discovery in the pharmaceutical industry. He gained a D.Phil in Biochemistry at the University of York and a BSc.(Hons) in Applied Biology from the University of Hertfordshire.
Max Nisen
Analyst
Bloomberg Intelligence
Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.
Vamsidhar Velcheti, MD
Director, Thoracic Oncology Program
New York University
As director of thoracic medical oncology at NYU Langone’s Perlmutter Cancer Center, Vamsidhar specializes in treating patients who have thoracic malignancies, such as lung cancer and mesothelioma. His research focuses on developing novel treatments called immunotherapy that can empower the patient’s immune system to fight cancer and discovering biomarkers to predict which patients could benefit from immunotherapy. He has lectured at national and international meetings and has been the recipient of several awards by the American Society of Clinical Oncology, including the Young Investigator Award in 2012, the Merit Award in 2013, and the Career Development Award in 2015.